Novartis AG - ADR
NVS
Get informed when a big investor buys or sells
+ FollowMarket Cap$268B
Close$
Earnings Call Q4 2025
February 4, 2026 - AI Summary
Strong Financial Performance: Novartis achieved an 8% sales increase and a 14% rise in core operating income for 2025, surpassing their guidance. They reached a core margin of 40.1%, two years earlier than planned, signaling strong operational execution and productivity improvements.
Sales Forecasts: For 2026, Novartis expects low single-digit sales growth, impacted by the entry of generics for key products like Entresto, Promacta, and Tasigna. The first half of 2026 is expected to see sales declining low single digit, while growth is anticipated in the second half, with mid-single-digit growth driven by priority brands.
Pipeline and Growth Drivers: The company highlighted several growth drivers, including a 57% increase in Kisqali sales and a strong performance from Scemblix and Pluvicto. Upcoming pivotal readouts for key pipeline products like pelabresib and remibrutinib are expected to bolster growth potential beyond 2026.
Exclusive for Stockcircle Pro members
Sign up
$185.44
31.5% upside
Current Fair Value
31.5% upsideUndervalued by 31.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $268.00 Billion |
|---|---|
| Enterprise Value | $309.31 Billion |
| Dividend Yield | $4.74 (3.18%) |
| Earnings per Share | $7.25 |
| Beta | 0.42 |
| Outstanding Shares | 1,905,000,000 |
Return
| Return on Equity | 30.50% |
|---|---|
| Return on Assets | 10.38% |
| Return on Invested Capital | 19.07% |
Valuation & Multiples
| P/E Ratio | 21.3 |
|---|---|
| PEG | -101.34 |
| Price to Sales | 5.04 |
| Price to Book Ratio | 6.71 |
| Enterprise Value to Revenue | 5.65 |
| Enterprise Value to EBIT | 18.01 |
| Enterprise Value to Net Income | 24 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 1.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 21, 2026
EPS Estimate
$2.17
Average shareholder expectationRevenue Estimate
$14.07 B
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$2.24
Average shareholder expectationRevenue Estimate
$14.61 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.9149▼ 22.89% |
|---|---|
| Total Calls | 2,352,882▲ 42.77% |
| Total Puts | 4,505,556▲ 27.53% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 7.15%▼ 0.41% |
|---|---|
| Total Invested | $21.34B▼ 3.17% |
| Investors Holding | 1,673▲ 33.00% |
ESG Score
No data
About Novartis AG
CEO: Vasant Narasimhan Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segm...